A topological algorithm was employed to establish a protein–interaction network (PPI), which identified nine key targets for AS in AD treatment: amyloid-beta precursor protein (APP), neurotrophic receptor tyrosine kinase 1 (NTRK1), estrogen receptor alpha (ESR1), cystic fibrosis transmembrane conductance regulator (CFTR), casein kinase 2 alpha 1 (CSNK2A1), epidermal growth factor receptor (EGFR), estrogen receptor 2 (ESR2), glycogen synthase kinase 3 beta (GSK3B), and P21 activated kinase 1 (PAK1). This evidence concerns the gene APP and Alzheimer disease.